Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206302502> ?p ?o ?g. }
- W4206302502 abstract "The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the two phase 3 SIMPLIFY trials consistently demonstrated high rates of sustained transfusion-independence. In a recent phase 2 translational study, 41% of the patients achieved transfusion independence for ≥ 12 weeks. In the phase 3 trials SIMPLIFY-1 and SIMPLIFY-2, 17% more JAK inhibitor-naïve patients and two-fold more JAK inhibitor-treated patients achieved or maintained transfusion independence with momelotinib versus ruxolitinib and best available therapy (89% ruxolitinib), respectively. Anemia is present in approximately a third of MF patients at diagnosis, eventually developing in nearly all patients. The need for red blood cell transfusions is an independent adverse risk factor for both overall survival and leukemic transformation. Presently, FDA-approved medications to address anemia are lacking. Momelotinib is one of the prime candidates to durably address the critical unmet needs of MF patients with moderate/severe anemia. Importantly, momelotinib may have overall survival benefits in frontline and second-line MF patients. MOMENTUM is an international registration-track phase 3 trial further assessing momelotinib's unique constellation of anemia and other benefits in second-line MF patients; the results of the MOMENTUM trial are keenly awaited and may lead to regulatory approval of momelotinib." @default.
- W4206302502 created "2022-01-25" @default.
- W4206302502 creator A5005670674 @default.
- W4206302502 creator A5013173470 @default.
- W4206302502 creator A5085521139 @default.
- W4206302502 date "2022-01-19" @default.
- W4206302502 modified "2023-10-14" @default.
- W4206302502 title "Momelotinib: an emerging treatment for myelofibrosis patients with anemia" @default.
- W4206302502 cites W1534089060 @default.
- W4206302502 cites W1980724348 @default.
- W4206302502 cites W1988123751 @default.
- W4206302502 cites W2005661051 @default.
- W4206302502 cites W2008799537 @default.
- W4206302502 cites W2009988274 @default.
- W4206302502 cites W2016406604 @default.
- W4206302502 cites W2023680965 @default.
- W4206302502 cites W2049912996 @default.
- W4206302502 cites W2049965335 @default.
- W4206302502 cites W2059184565 @default.
- W4206302502 cites W2071990094 @default.
- W4206302502 cites W2085253297 @default.
- W4206302502 cites W2085287321 @default.
- W4206302502 cites W2089753725 @default.
- W4206302502 cites W2105127732 @default.
- W4206302502 cites W2115351357 @default.
- W4206302502 cites W2121743767 @default.
- W4206302502 cites W2123633897 @default.
- W4206302502 cites W2125469922 @default.
- W4206302502 cites W2127559749 @default.
- W4206302502 cites W2129475142 @default.
- W4206302502 cites W2132155262 @default.
- W4206302502 cites W2139011653 @default.
- W4206302502 cites W2149055075 @default.
- W4206302502 cites W2161021913 @default.
- W4206302502 cites W2170885365 @default.
- W4206302502 cites W2176736150 @default.
- W4206302502 cites W2294536664 @default.
- W4206302502 cites W2333290716 @default.
- W4206302502 cites W2405712018 @default.
- W4206302502 cites W2511586498 @default.
- W4206302502 cites W2521045502 @default.
- W4206302502 cites W2553766069 @default.
- W4206302502 cites W2555002983 @default.
- W4206302502 cites W2564597498 @default.
- W4206302502 cites W2586215211 @default.
- W4206302502 cites W2594933518 @default.
- W4206302502 cites W2598479043 @default.
- W4206302502 cites W2612868058 @default.
- W4206302502 cites W2622547803 @default.
- W4206302502 cites W2731573311 @default.
- W4206302502 cites W2734585076 @default.
- W4206302502 cites W2754551124 @default.
- W4206302502 cites W2757643721 @default.
- W4206302502 cites W2759277150 @default.
- W4206302502 cites W2768672347 @default.
- W4206302502 cites W2768722269 @default.
- W4206302502 cites W2776878294 @default.
- W4206302502 cites W2778275419 @default.
- W4206302502 cites W2780688021 @default.
- W4206302502 cites W2791240656 @default.
- W4206302502 cites W2791956198 @default.
- W4206302502 cites W2793337215 @default.
- W4206302502 cites W2804579795 @default.
- W4206302502 cites W2887425495 @default.
- W4206302502 cites W2911052269 @default.
- W4206302502 cites W2911765035 @default.
- W4206302502 cites W2911912494 @default.
- W4206302502 cites W2912217799 @default.
- W4206302502 cites W2912641686 @default.
- W4206302502 cites W2913615892 @default.
- W4206302502 cites W2964465172 @default.
- W4206302502 cites W2973044926 @default.
- W4206302502 cites W2973305257 @default.
- W4206302502 cites W2988253820 @default.
- W4206302502 cites W2991431537 @default.
- W4206302502 cites W2996087467 @default.
- W4206302502 cites W2999262601 @default.
- W4206302502 cites W3008023739 @default.
- W4206302502 cites W3009670005 @default.
- W4206302502 cites W3010774459 @default.
- W4206302502 cites W3012454590 @default.
- W4206302502 cites W3016444371 @default.
- W4206302502 cites W3017637294 @default.
- W4206302502 cites W3022959153 @default.
- W4206302502 cites W3026423379 @default.
- W4206302502 cites W3029926323 @default.
- W4206302502 cites W3031846212 @default.
- W4206302502 cites W3041411480 @default.
- W4206302502 cites W3045198911 @default.
- W4206302502 cites W3049006724 @default.
- W4206302502 cites W3085980128 @default.
- W4206302502 cites W3088252095 @default.
- W4206302502 cites W3092168378 @default.
- W4206302502 cites W3096573094 @default.
- W4206302502 cites W3097677520 @default.
- W4206302502 cites W3110249225 @default.
- W4206302502 cites W3119071615 @default.
- W4206302502 cites W3120572889 @default.
- W4206302502 cites W3141140978 @default.
- W4206302502 cites W3148770953 @default.